Clinical Trials
6 trialsNCT04635683 2022-09-30
Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 1 Withdrawn
NCT01744912 2022-05-11
Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies
TG Therapeutics, Inc.
Phase 1 Terminated
NCT01429025 2019-10-08
Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Refractory or Relapsed Indolent Non-Hodgkin Lymphoma
Alliance for Clinical Trials in Oncology
Phase 1 Completed
NCT01254578 2017-09-25
Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers
National Cancer Institute (NCI)
Phase 1 Completed
NCT01045928 2015-11-26
Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma
Case Comprehensive Cancer Center
Phase 1 Terminated
NCT01116154 2010-12-09
Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
City of Hope Medical Center
Phase 1 Terminated